financetom
Business
financetom
/
Business
/
RBL Bank expects dip in new credit cards, spends in FY21
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
RBL Bank expects dip in new credit cards, spends in FY21
May 17, 2020 4:26 AM

RBL Bank, which derives 18 percent of its loan portfolio from credit cards, is expecting new plastic issuances to halve and a fall in spends as well in FY21 but is confident of the overall revenues from the segment remaining intact, a senior official has said.

However, the economic climate will result in an increase in credit costs, or money being set aside for possible loan losses, by over 30 percent in the cards segment, the official told PTI.

Usually, banks have a lower reliance on the credit cards segment for their advances because it is an unsecured product, but it's segmental head Harjeet Toor said the bank has been using a slew of analytics capabilities to grow in the category without increasing its delinquencies.

He explained that revenues will be stable largely on the back of the three months' moratorium in loan repayments announced by the RBI, as interests keep getting compounded for the non-payees, adding to its overall income.

Nearly a fourth of its overall credit card portfolio of Rs 10,500 crore has opted for the moratorium, he said.

"Our revenues are split evenly between fees and interest income. What we will lose on fees like lower spends, cross-sell and penalty for delayed payments, we will recover through an increase in interest. We expect revenues to be stable," he said.

According to an investor presentation, in FY20, fees from credit cards contributed Rs 942.3 crore, accounting for 54 percent of the overall core fee income, which suggests that overall revenues from the credit card to be in the vicinity of Rs 1,900 crore.

Also Read:

5 myths about credit cards that you shouldn't believe

As a prudential measure, the bank locks up the ability to use the cards for newer spends in cases of those customers who've opted for the moratorium, Toor said, adding that only 13 per cent of the customers by number have opted for the RBI-announced relief and sounded confident of it to come down even if the moratorium is extended.

In FY21, it expects to sell only over 5 lakh credit cards as against the 13 lakh earlier, Toor said, adding that it has to wait for a few months before the market actually settles down.

In April, there was negligible new acquisitions and the overall portfolio remained at 28 lakh cards, he said, adding that it will be slow in expanding the base at least till the post-monsoon festivities.

With over 60 percent of its customers being a resident of the 'red zones', spends have also taken a hit, Toor said, pointing out that spends on aspects like groceries and utilities have held on.

In FY21, the bank expects a 12 percent dip in overall spends, through which it derives an interchange fee, as per the investor presentation.

Toor said the reduction in spends will not be very pronounced because the bank does not depend on discretionary spending categories like restaurants and cinema which are likely to be affected more.

From a portfolio quality perspective, he said the credit costs will be up by 30-60 percent due to the overall climate, but added that it has been using a host of levers to reduce it delinquencies.

It's overall gross non-performing assets from the cards business reduced to 1.2 percent in March as against 1.67 percent, he said, adding that its delinquencies are 27 percent lower than peers.

It uses strategies like age group, where it focuses on those above 30, tie-ups with brands like Bajaj Finance and Zomato to give it data analytics, and also avoiding fresh to credit card segment people to keep the NPAs under check, he said.

First Published:May 17, 2020 1:26 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Canada's Metro slightly misses Q4 sales estimates
Canada's Metro slightly misses Q4 sales estimates
Nov 19, 2025
Overview * Metro Q4 sales rose 3.4% but slightly missed analyst expectations * Adjusted EPS for Q4 beats consensus, rising 10.8% * Net earnings impacted by $22.5 mln due to Toronto distribution centre shutdown Outlook * Metro expects $15-20 mln impact on Q1 2026 net earnings from distribution center shutdown * Company plans to open about a dozen new or...
Auto services chain Valvoline's Q4 profit misses
Auto services chain Valvoline's Q4 profit misses
Nov 19, 2025
Overview * Valvoline ( VVV ) Q4 sales rise 4% to $454 mln, system-wide SSS grow 6% * Adjusted EPS for Q4 misses analyst expectations, decreasing by 2% * Company to close Breeze Autocare acquisition, adding 162 stores to network Outlook * Valvoline ( VVV ) expects fiscal 2026 net revenues of $2.0 - $2.1 bln * Company forecasts fiscal...
ThirdGen Timber Group Acquires Majority Stake in Canadian Timberframes Uniting Industry Leaders in Log, Timber, and Mass Timber Construction
ThirdGen Timber Group Acquires Majority Stake in Canadian Timberframes Uniting Industry Leaders in Log, Timber, and Mass Timber Construction
Nov 19, 2025
MUSKOKA, ON and GOLDEN, BC, Nov. 19, 2025 /PRNewswire/ - ThirdGen Timber Group, parent company of True North Log & Timber Homes and Legacy North Construction Management, has announced that it has acquired a majority stake in Canadian Timberframes Ltd., one of Canada's most respected and established timber frame manufacturers. This transformational partnership brings together Canada's leading log and timber...
Hanmi Pharmaceutical to Buy Aptose Biosciences for $2.41 a Share
Hanmi Pharmaceutical to Buy Aptose Biosciences for $2.41 a Share
Nov 19, 2025
07:09 AM EST, 11/19/2025 (MT Newswires) -- Aptose Biosciences ( APTOF ) said earlier Wednesday that it is being acquired by Hanmi Pharmaceutical at $2.41 per share. The price is a 28% premium over Aptose's 30-day VWAP of $1.88 on the Toronto Stock Exchange. Over the past 18 months, Hanmi, who already has a near 20% stake in Aptose, has...
Copyright 2023-2026 - www.financetom.com All Rights Reserved